Aldeyra Therapeutics Inc (ALDX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Todd C. Brady
Employees:
10
131 HARTWELL AVENUE, SUITE 320, LEXINGTON, MA 02421
781-761-4904

Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.

Data derived from most recent annual or quarterly report
Market Cap 435.101 Million Shares Outstanding58.56 Million Avg 30-day Volume 516.115 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.25
Price to Revenue0.0 Debt to Equity0.0754 EBITDA-55.546 Million
Price to Book Value1.0507 Operating Margin0.0 Enterprise Value1.881 Million
Current Ratio19.771 EPS Growth0.036 Quick Ratio19.519
1 Yr BETA 1.1301 52-week High/Low 8.08 / 2.36 Profit Margin0.0
Operating Cash Flow Growth-13.5022 Altman Z-Score3.3054 Free Cash Flow to Firm -34.057 Million
Earnings Report2023-05-04
View SEC Filings from ALDX instead.

View recent insider trading info

Aldeyra Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ALDX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALDX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-02 by MACHATHA STEPHEN
  • 4: filed on 2023-03-02 by GREENBERG BRUCE
  • 4: filed on 2023-03-02 by BRADY TODD C
  • 4: filed on 2022-08-10 by EDELMAN JOSEPH
  • 4: filed on 2022-08-05 by EDELMAN JOSEPH
  • 4: filed on 2022-08-04 by EDELMAN JOSEPH
  • 4: filed on 2022-08-03 by EDELMAN JOSEPH
  • 4: filed on 2022-08-02 by EDELMAN JOSEPH
  • 4: filed on 2022-08-01 by EDELMAN JOSEPH
  • 4: filed on 2022-07-19 by BRADY TODD C

    • Events (8k)

  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-02:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-01:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-06:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BRADY TODD C PRESIDENT AND CEO

    • Officer
    • Director
    		 1,455,285 2023-02-28 4

    MACHATHA STEPHEN CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2023-02-28 3

    GREENBERG BRUCE SEE REMARKS

    • Officer
    		 0 2023-02-28 3

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • 10% Owner
    		 11,350,085 2022-08-09 9

    JOYCE MARTIN JOSEPH

    • Director
    		 23,967 2022-06-23 2

    DOUGLAS RICHARD

    • Director
    		 69,353 2022-06-07 1

    PHILLIPS GARY M.

    • Director
    		 61,930 2022-06-07 1

    WALKER NEAL

    • Director
    		 56,131 2022-06-07 1

    BRONSTEIN BEN

    • Director
    		 61,002 2022-06-07 1

    MILLER-RICH NANCY

    • Director
    		 56,131 2022-06-07 1

    REED JOSHUA CHIEF FINANCIAL OFFICER

    • Officer
    		 524,825 2022-03-30 1

    TREU JESSE I

    • Director
    		 0 2020-06-09 0

    MCMULLIN DAVID CHIEF COMMERCIAL OFFICER

    • Officer
    		 255,183 2020-03-02 0

    CLARK DAVID J CHIEF MEDICAL OFFICER

    • Officer
    		 17,878 2019-09-06 0

    TULIPANO STEPHEN J CHIEF FINANCIAL OFFICER

    • Officer
    		 8,563 2018-03-06 0

    CLARKE C. BOYD

    • Director
    		 0 2016-06-09 0

    YOUNG SCOTT CHIEF OPERATING OFFICER

    • Officer
    		 0 2016-03-16 0

    SHAH NIMESH

    • 10% Owner
    		 10,358 2015-01-01 0

    DOMAIN PARTNERS VI, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    • Director
    • 10% Owner
    		 1,973,389 2014-05-07 0

    JOHNSON & JOHNSON

    JOHNSON & JOHNSON DEVELOPMENT CORP ET AL

    • 10% Owner
    		 0 2014-05-01 0

    DOMAIN ASSOCIATES

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    KAMDAR KIM P.

    • Director
    • 10% Owner
    		 10,358 2014-05-01 0

    DP VI ASSOCIATES, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    • Director
    • 10% Owner
    		 0 2014-05-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BRADY TODD C - Director - Officer PRESIDENT AND CEO

    		2023-03-02 16:22:33 -0500 2023-02-28 A 238,750 a 1,455,285 direct -1.6043 -4.0107 5.615 5 -4.0107 6

    BRADY TODD C - Director - Officer PRESIDENT AND CEO

    		2023-03-02 16:22:33 -0500 2023-02-28 A 250,000 a 250,000 direct

    MACHATHA STEPHEN - Officer CHIEF DEVELOPMENT OFFICER

    		2023-03-02 16:27:10 -0500 2023-02-28 A 220,258 a 220,258 direct

    GREENBERG BRUCE - Officer SEE REMARKS

    		2023-03-02 16:25:46 -0500 2023-02-28 A 110,028 d 110,028 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 20:45:03 UTC 4.1561 0.4139 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 20:15:04 UTC 4.1561 0.4139 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 19:45:04 UTC 4.1561 0.4139 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 19:15:03 UTC 4.1561 0.4139 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 18:45:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 18:15:05 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 17:45:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 17:15:04 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 16:45:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 16:15:04 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 15:45:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 15:15:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 14:45:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 14:15:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 13:45:04 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 13:15:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-22 12:45:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-21 22:15:04 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-21 21:45:03 UTC 4.1486 0.4214 1700000
    ALDEYRA THERAPEUTICS INC ALDX 2023-03-21 21:15:03 UTC 4.1486 0.4214 1700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments